KITE PHARMA, INC.

Galapagos CFO and COO Thad Huston to Depart as Company Advances Cell Therapy Transformation

a month ago

• Thad Huston, CFO and COO of Galapagos NV, will leave the company effective August 1, 2025, returning to the U.S. for personal and professional reasons. • During his two-year tenure since joining from Kite Pharma in 2023, Huston supported Galapagos' strategic transformation into a focused cell therapy company with a unique decentralized platform. • Galapagos expects to announce Huston's successor in the coming months, with the departing executive remaining until August to ensure a smooth transition of responsibilities.

CAR T-cell Therapy Monitoring: Study Suggests Reduced REMS May Improve Accessibility

8 months ago

• A recent study suggests that the FDA's Risk Evaluation and Mitigation Strategy (REMS) for CAR T-cell therapy may be overly restrictive, impacting patient accessibility. • The study found that the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) is low after the first two weeks post-CAR T infusion. • Researchers propose a more flexible approach to monitoring, with a mandatory 2-week period near the treatment center, followed by individualized assessments. • Revisiting REMS mandates could reduce the physical and financial burden on patients, potentially improving access to CAR T-cell therapy, especially for underserved populations.